




# Safety and efficacy of durvalumab plus tremelimumab in older individuals with unresectable hepatocellular carcinoma : a multicenter analysis



	Older individuals	Younger individuals	p value
Objective response rate	15.6%	22.5%	0.221
Disease control rate	45.0%	53.9%	0.216

The incidence of immune-mediated adverse events did not differ significantly between older and younger individuals.

**Durvalumab plus tremelimumab appears to be a safe and effective treatment option for patients with HCC, regardless of age.**